08.03.2011 • NewsActelionElliott Advisors

Rudolf Maag Gives Backing to Actelion

Actelion, Europe's largest biotech company, has the backing of Rudolf Maag, one its largest shareholders, a spokeswoman for Maag said on Monday.

The company is coming under pressure from hedge fund activist Elliott Advisors ahead of the group's annual general meeting in May.
Elliott, Actelion's biggest shareholder with a near 6% stake, is dissatisfied with the group's performance and is pushing Actelion to consider selling itself.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.